for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bio-Rad Laboratories, Inc.

BIO.N

Latest Trade

524.13USD

Change

-1.09(-0.21%)

Volume

71,835

Today's Range

520.32

 - 

526.16

52 Week Range

314.89

 - 

539.56

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
525.22
Open
524.64
Volume
71,835
3M AVG Volume
5.73
Today's High
526.16
Today's Low
520.32
52 Week High
539.56
52 Week Low
314.89
Shares Out (MIL)
29.68
Market Cap (MIL)
15,586.56
Forward P/E
74.07
Dividend (Yield %)
--

Next Event

Q3 2020 Bio Rad Laboratories Inc Earnings Release

Latest Developments

More

Bio Rad Laboratories Reports Q2 Earnings Per Share $32.15

Bio Rad Laboratories Estimates Q2 Currency-Neutral Sales To Decline By 5% To 10%

Bio-Rad Reports Q1 Non-GAAP Earnings Per Share $1.91

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Life Science segment markets and develops, manufactures and markets approximately 6,000 reagents, apparatus and laboratory instruments. Its products are used in research techniques, biopharmaceutical production processes and food testing regimes. Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market.

Industry

Scientific & Technical Instr.

Contact Info

1000 ALFRED NOBEL DR

HERCULES, CA

94547-1811

United States

+1.510.7247000

http://www.bio-rad.com/

Executive Leadership

Norman D. Schwartz

Chairman of the Board, President, Chief Executive Officer

Ilan Daskal

Chief Financial Officer, Executive Vice President

Andrew J. Last

Chief Operating Officer, Executive Vice President

Timothy Scott Ernst

Executive Vice President, General Counsel, Secretary

Michael Crowley

Executive Vice President - Global Commercial Operations

Key Stats

1.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

2.2K

2018

2.3K

2019

2.3K

2020(E)

2.3K
EPS (USD)

2017

2.010

2018

5.840

2019

7.060

2020(E)

7.922
Price To Earnings (TTM)
8.15
Price To Sales (TTM)
6.80
Price To Book (MRQ)
2.12
Price To Cash Flow (TTM)
7.48
Total Debt To Equity (MRQ)
5.97
LT Debt To Equity (MRQ)
0.17
Return on Investment (TTM)
23.79
Return on Equity (TTM)
21.95

Latest News

Latest News

BRIEF-Bio Rad Laboratories Estimates Q2 Currency-Neutral Sales To Decline By 5% To 10%

* BIO RAD LABORATORIES SAYS IT EXPECTS Q2 2020 YEAR-OVER-YEAR CURRENCY NEUTRAL SALES MAY DECLINE BY 5 TO 10 PERCENT - SEC FILING Source text: (https://bit.ly/3glQfJ0) Further company coverage:

BRIEF-Bio-Rad Reports Q1 Non-GAAP Earnings Per Share $1.91

* Q1 EARNINGS PER SHARE ESTIMATE $1.57 -- REFINITIV IBES DATA

BRIEF-Bio-Rad Receives FDA Emergency Use Authorization For Droplet Digital Pcr Sars-Cov-2 Test Kit

* BIO-RAD RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR DROPLET DIGITAL PCR SARS-COV-2 TEST KIT Source text for Eikon: Further company coverage:

BRIEF-Bio-Rad Begins Shipping COVID-19 Antibody Test

* BIO-RAD BEGINS SHIPPING SARS-COV-2 (COVID-19) ANTIBODY TEST THAT OFFERS MORE THAN 99 PERCENT SPECIFICITY AND 98 PERCENT SENSITIVITY Source text for Eikon: Further company coverage:

BRIEF-Bio-Rad Acquires Celsee Inc

* BIO-RAD ACQUIRES CELSEE, INC., A SINGLE-CELL ANALYSIS SOLUTIONS PROVIDER

BRIEF-Bio-Rad To Launch Serology Assay To Detect Coronavirus Antibodies

* BIO-RAD ANNOUNCES THE LAUNCH OF A SEROLOGY ASSAY TO DETECT CORONAVIRUS (COVID-19) ANTIBODIES

BRIEF-Biodesix Partners With Bio-Rad To Bring Emergency Use Authorization Covid-19 Ddpcr Test To The U.S.

* BIODESIX PARTNERS WITH BIO-RAD TO BRING EMERGENCY USE AUTHORIZATION (EUA) COVID-19 DDPCR™ TEST TO THE U.S.

BRIEF-Bio-Rad Partners With Testing Labs Worldwide To Support Covid-19 Testing

* BIO-RAD PARTNERS WITH TESTING LABS WORLDWIDE TO SUPPORT COVID-19 TESTING Source text for Eikon: Further company coverage:

BRIEF-Bio-Rad Reports Q4 Non-Gaap Earnings Per Share $2.32

* BIO-RAD REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS

CORRECTED-(OFFICIAL)-BRIEF-Bio-Rad Posts Q2 EPS Of $19.86 (Aug. 1)

* Q2 SALES $572.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $566.2 MILLION

BRIEF-Bio-Rad Q1 Earnings Per Share $21.77

* Q1 EARNINGS PER SHARE VIEW $1.07 -- THOMSON REUTERS I/B/E/S

BRIEF-Bio Rad Laboratories Says CEO Norman Schwartz's 2017 Total Compensation Was $5.4 Mln Vs $4.9 Mln In 2016

* BIO RAD LABORATORIES INC SAYS CEO NORMAN SCHWARTZ'S 2017 TOTAL COMPENSATION WAS $5.4 MILLION VERSUS $4.9 MILLION IN 2016 – SEC FILING Source text: (https://bit.ly/2KCpD6p) Further company coverage:

BRIEF-Bio Rad Laboratories Says KPMG Notified Senior Management It Required More Time To Complete Audit Of 2017 Financial Statements

* BIO RAD LABORATORIES - KPMG NOTIFIED SENIOR MANAGEMENT IT REQUIRED MORE TIME TO COMPLETE AUDIT OF 2017 FINANCIAL STATEMENTS - SEC FILING

BRIEF-Bio Rad Laboratories Files For Non-Timely 10-K - SEC Filing

* BIO RAD LABORATORIES FILES FOR NON-TIMELY 10-K - SEC FILING Source text (http://bit.ly/2FeZn29) Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Bio-Rad Q4 Earnings Per Share $2.32

* BIO-RAD REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

BRIEF-Bio-Rad Gains Additional U.S. FDA Clearances

* BIO-RAD GAINS ADDITIONAL U.S. FDA CLEARANCES FOR BLOOD TYPING PRODUCTS, EXPANDING ITS OFFERING FOR BLOOD TESTING MARKET Source text for Eikon: Further company coverage:

BRIEF-Bio-Rad Authorizes New $250 Million Share Repurchase Program

* BIO-RAD AUTHORIZES NEW $250 MILLION SHARE REPURCHASE PROGRAM

BRIEF-Bio Rad Laboratories reports Q3 earnings per share $0.91

* Bio Rad Laboratories Inc reports third-quarter 2017 financial results

BRIEF-U.S. ITC to probe certain 10X Genomics devices after Bio-Rad complaint

* U.S. U.S. International Trade Commission says it will investigate certain microfluidic devices by 10x Genomics Inc after complaint by Bio-rad Laboratories Inc and Lawrence Livermore National Security LLC. Source text for Eikon: Further company coverage: (Reporting By Susan...

BRIEF-Bio-Rad reports Q2 earnings per share $0.17

* Q2 earnings per share view $0.56 -- Thomson Reuters I/B/E/S

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up